Search

Your search keyword '"Mizutani, Hideaki"' showing total 168 results

Search Constraints

Start Over You searched for: Author "Mizutani, Hideaki" Remove constraint Author: "Mizutani, Hideaki"
168 results on '"Mizutani, Hideaki"'

Search Results

2. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

5. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

6. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

7. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

9. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

10. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

11. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer

12. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)

13. MO1-1 LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab + ipilimumab +/- chemotherapy for NSCLC in Japan

14. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

16. Supplementary Figure 2 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells

17. Supplementary Figure 1 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells

19. P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan

21. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

22. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

23. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

27. Field Observations on Water Temperature and Salinity Fields in Tanabe Bay in 2016

28. 田辺中島高潮観測塔における2016年夏季観測結果

29. Water Temperature Measurements by Small-Sized Thermometers Installed on Riverbed in Neighboring Rivers of Tanabe Bay

30. Uncommon mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).

32. PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update

33. Field Measurements at Tanabe-Nakashima Observation Tower in the Summer of 2015

34. Numerical Simulation of Riverbed Variation in Tonda River Using Simplified Lagrangian Model of Bedload Transport

35. A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).

36. A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

37. REVISING WAVE INDUCED TURBULENT MIXING AND ITS IMPACT ON TROPICAL CYCLONE

42. Olanzapine 5mg in Combination with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy (J-FORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

43. Measurements of Morphological Changes in Tonda River Estuary

44. Field Measurements at Tanabe-Nakashima Observation Tower in the Summer of 2014

45. Observed Features of Langmuir Turbulence Forced by Misaligned Wind and Waves Under Destabilizing Buoyancy Flux

46. Field Measurements at Tanabe-Nakashima Observation Tower in the Summer of 2013

47. Study on Bed-load Sorting around Series of Spur-dikes

50. Clinical courses of peritoneal and pleural malignant mesothelioma, a single-center experience

Catalog

Books, media, physical & digital resources